Secondary prevention after coronary artery bypass grafting: Anticoagulation and antiplatelet therapy is only one...

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Outcomes Research

Background:

• Coronary artery bypass grafting (CABG) is a common surgical procedure for treating coronary artery disease.
• Antiplatelet and antithrombotic therapies are crucial components of post-CABG secondary prevention.
• The optimal antiplatelet strategy following CABG remains an area of active investigation.

Purpose of the Study:

• To evaluate the efficacy of dual antiplatelet therapy (DAPT) versus aspirin monotherapy in improving graft patency and clinical outcomes after CABG.
• To assess the impact of DAPT on bleeding risk in patients undergoing CABG.
• To explore potential differences in DAPT effectiveness between on-pump and off-pump CABG procedures.

Main Methods:

• Comparative analysis of clinical outcomes and graft patency rates in patients receiving DAPT (aspirin plus clopidogrel/ticagrelor/prasugrel) versus aspirin monotherapy post-CABG.
• Stratification of results based on surgical technique: on-pump versus off-pump CABG.
• Assessment of major bleeding incidence associated with different antiplatelet regimens.

Main Results:

• DAPT did not demonstrate improved graft patency or clinical outcomes compared to aspirin monotherapy in on-pump CABG.
• A trend towards greater protective effects of DAPT was observed in patients undergoing off-pump CABG.
• The addition of potent thienopyridines in DAPT increased the risk of major bleeding, although overall incidence remained low.

Conclusions:

• Aspirin monotherapy is as effective as DAPT for graft patency and clinical outcomes in on-pump CABG.
• DAPT may offer benefits in off-pump CABG, but requires careful consideration of increased bleeding risk.
• Post-CABG antiplatelet and antithrombotic therapy is a key, but not sole, component of comprehensive secondary prevention strategies.